Correlation Between Biofil Chemicals and Nucleus Software

Can any of the company-specific risk be diversified away by investing in both Biofil Chemicals and Nucleus Software at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biofil Chemicals and Nucleus Software into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Biofil Chemicals Pharmaceuticals and Nucleus Software Exports, you can compare the effects of market volatilities on Biofil Chemicals and Nucleus Software and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biofil Chemicals with a short position of Nucleus Software. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biofil Chemicals and Nucleus Software.

Diversification Opportunities for Biofil Chemicals and Nucleus Software

0.39

Correlation Coefficient

Biofil Chemicals  Nucleus Software

Weak diversification

The 3 months correlation between Biofil and Nucleus is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Biofil Chemicals Pharmaceutica and Nucleus Software Exports in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nucleus Software Exports and Biofil Chemicals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biofil Chemicals Pharmaceuticals are associated (or correlated) with Nucleus Software. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nucleus Software Exports has no effect on the direction of Biofil Chemicals i.e., Biofil Chemicals and Nucleus Software go up and down completely randomly.

Pair Corralation between Biofil Chemicals and Nucleus Software

Assuming the 90 days trading horizon Biofil Chemicals Pharmaceuticals is expected to generate 2.52 times more return on investment than Nucleus Software. However, Biofil Chemicals is 2.52 times more volatile than Nucleus Software Exports. It trades about 0.01 of its potential returns per unit of risk. Nucleus Software Exports is currently generating about -0.2 per unit of risk. If you would invest  6,376  in Biofil Chemicals Pharmaceuticals on September 3, 2024 and sell it today you would lose (95.00) from holding Biofil Chemicals Pharmaceuticals or give up 1.49% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Biofil Chemicals Pharmaceutica  vs.  Nucleus Software Exports

Biofil Chemicals Pha

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Biofil Chemicals Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound technical indicators, Biofil Chemicals is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Nucleus Software Exports

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Nucleus Software Exports has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Biofil Chemicals and Nucleus Software

The main advantage of trading using opposite Biofil Chemicals and Nucleus Software positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biofil Chemicals position performs unexpectedly, Nucleus Software can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nucleus Software will offset losses from the drop in Nucleus Software's long position.

The idea behind Biofil Chemicals Pharmaceuticals and Nucleus Software Exports pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.